ASMB - Latest News

Assembly Biosciences, Inc. (ASMB), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $653.0M. Beta to the broader market is 1.09.

The article list below shows the most recent ASMB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ASMB Headlines

Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal

seekingalpha.com - Aug 16, 2026

Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

zacks.com - Aug 13, 2026

Assembly Biosciences (ASMB) came out with a quarterly loss of $0. 2 per share versus the Zacks Consensus Estimate of a loss of $0.

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

globenewswire.com - Aug 13, 2026

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangit

Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates

seekingalpha.com - Jul 18, 2026

Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead and a strengthened

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

marketbeat.com - Jun 8, 2026

Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sach

How News Affects ASMB Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ASMB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ASMB news questions

What is the latest ASMB news headline?

The most recent ASMB headline (Aug 16, 2026) is "Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ASMB news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ASMB news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ASMB options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.